NDAORALTABLETPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
15
Mechanism of Action
Gamma Secretase Inhibitors
Pharmacologic Class:
Gamma Secretase Inhibitor
Clinical Trials (5)
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants
Started Nov 2025
16 enrolled
Healthy
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Started Sep 2025
50 enrolled
Desmoid TumorAggressive Fibromatosis
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Started Sep 2025
24 enrolled
Healthy
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Started Aug 2025
18 enrolled
Desmoid TumorAggressive Fibromatosis
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Started Nov 2024
Loss of Exclusivity
LOE Date
May 19, 2043
209 months away
Patent Expiry
May 19, 2043
Exclusivity Expiry
Nov 27, 2030